MarketPulse

ImmunityBio

3 articles
The Motley FoolThe Motley Fool··James Brumley

ImmunityBio Surges 11% on First Asian Approval for Bladder Cancer Drug

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.
IBRXAsia-Pacific expansionbladder cancer
BenzingaBenzinga··Vandana Singh

ImmunityBio Expands European Presence With 85-Person Sales Team for Bladder Cancer Drug

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.
IBRXEuropean expansionbladder cancer
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer